As we hit the Q2/Q3 mark in this very hot summer, the hires chatter is not exactly heating up, but we did see a steady beat of news in July, including a lot of new CEOs.
We normally only segment our hires roundup into three categories, but for the May-June double issue we had enough non-profit, professional organisation, and government hires to spin them of
Welcome to the third part of our hires roundup for May and June, where we look at digital health and medtech hires, as well as various suppliers and support functions in life sciences, like
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.